PharmaMar plans to propose at its next ordinary general shareholders' meeting, convened for the second call on June 30, 2026, the payment of a dividend of one euro per share and the renewal for four years of Sandra Ortega Mera and Chairman José María Fernández Sousa-Faro as board members, according to documentation sent this Thursday to the National Securities Market Commission (CNMV).
The board of directors has decided to submit to the meeting the proposal to pay shareholders a gross dividend of one euro for each outstanding share, charged to freely disposable reserves (share premium), up to a total ceiling of 18 million euros.
The final amount will be set at the time of payment, depending on the number of outstanding shares and the shares held in treasury stock, and the dividend will be paid on July 10 through Banco Santander, following Iberclear's operational rules.
The company will also submit for approval a plan for the delivery of treasury shares of PharmaMar to employees and executives of the group for the 2027 fiscal year, with the aim of "fostering their participation in the share capital and incentivizing their retention".
This program contemplates the distribution of up to 41,000 shares, free of charge or not, for all employees and executives of the group's various companies, provided that the established conditions are met, including a minimum seniority of six months.
The market value of the shares received by each beneficiary will have a maximum limit of 12,000 euros and, added to other benefits in kind received in 2027, cannot exceed 30% of their annual salary.
In the corporate governance section, the agenda includes the re-election of Sandra Ortega Mera, daughter of Amancio Ortega and president of the holding company Rosp Corunna, as a proprietary director for a new statutory term of four years, as well as the continuation for the same period of José María Fernández Sousa-Faro as executive director and chairman.
The board will also propose extending the term of Emiliano Calvo Aller as an independent director and Pedro Fernández Puentes as an executive director for four years, and will submit for vote the incorporation of María Victoria Mateos Manteca and Juan Manuel Vieites Baptista de Sousa as new independent directors. At the close of the meeting, the terms of Rosa María Sánchez-Yebra Alonso and Mariano Esteban Rodríguez will expire.
Finally, the call includes the authorization for the group to make simple contributions to the PharmaMar Foundation for a maximum amount of 800,000 euros per fiscal year, expressly conditioned on the consolidated group obtaining profits, along with other matters provided for on the agenda.